Pattern’s ovarian cancer combination candidate shows promising in vivo results

image credit- shutterstock

Pattern Computer has announced that its ovarian cancer combination candidate has demonstrated promising synergy and efficacy in an in vivo study against human ovarian cancer xenografts in mouse models. This follows initial potential synergy observed in in vitro studies conducted at a leading global clinical research organization.

Pattern’s combination drug targets high-grade serous ovarian cancer (HGSOC), the most common and deadliest form of gynecologic cancer. Combination therapy is a promising strategy for effectively treating cancer due to its improved efficacy and reduced toxicity. However, the large number of possible combinations makes screening for synergistic drug pairs laborious and expensive.

Pattern has developed a cutting-edge computational platform called the Pattern Discovery Engine (PDE). This platform identifies therapeutically exploitable gene interactions, enabling the rapid identification and development of synergistic drug combinations against multifactorial diseases, such as cancer and diabetes among others.

Mark Anderson, Chair and CEO of Pattern, stated, “This important discovery underscores the potential of our PDE to uncover novel therapeutic combinations for hard-to-treat cancers like HGSOC.”